Genomics could guide the decision about whether a patient should undergo implant reconstruction or autologous tissue-based reconstruction.
There is a push to create innovative adaptive trial designs that include more patients and, subsequently, more generalizable data.
The likelihood of a patient with breast cancer receiving genetic analysis more than doubled if she went to a surgeon with a high propensity for ordering such tests.
Circulating tumor DNA levels measured as early as 3 weeks post-therapy may provide clues about long-term outcomes in this lymphoma subtype.
A meta-analysis compared outcomes between the use of partial nephrectomy using a robotic surgical approach and open or laparoscopic partial nephrectomy.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|